TruVivo was developed to fill the need for convenient yet robust in vitro platform that maintains phenotypically stable and functional primary human hepatocytes. Because of these qualities, the system serves a basic platform for answering a wide range of questions pertaining to preclinical drug development. One challenge is the need to create a multicellular system that has the biological complexity required to answer today's questions, yet is still easy to use.
Current systems often fail to maintain hepatocyte morphology and function long-term or present technical challenges with establishing routine, reproducible results. With TruVivo, users can still rely on the simplicity and flexibility of traditional 2D cell culture techniques. Additionally, there is no special equipment required, and the system is amenable to traditional analytical methods.
With TruVivo, we are now able to predict metabolic clearance, major metabolites, key pathways of elimination, and other pharmacokinetic properties of compounds more accurately with long half-lives prior to preclinical evaluation.
